Absorption Systems L.P., 436 Creamery Way, Suite 600, Exton, PA 19341-2556.
Drug Metab Dispos. 2011 Jul;39(7):1196-202. doi: 10.1124/dmd.111.038075. Epub 2011 Mar 29.
The objective of the present study was to determine the efflux transporters responsible for acid and lactone statin drug efflux using transporter knockdown Caco-2 cells. The bidirectional transport was determined in Caco-2 cell monolayers in which the expression of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or multidrug resistance associated protein 2 (MRP2) was knocked down by transduction with lentivirus containing human transporter-targeted small hairpin RNAs (shRNAs). Cells transduced with lentivirus containing nontargeted shRNA served as the vector control. Atorvastatin, lovastatin, and rosuvastatin displayed extremely low apical-to-basolateral (A-to-B) transport, which made the P(app,A-B) values too unreliable to calculate the efflux ratio. Thus, transport comparisons were performed using the B-to-A permeability (P(app,B-A)) values. Presented in the order of vector control, P-gp, BCRP, and MRP2 knockdown Caco-2 cells, the P(app,B-A) values (×10(-6), cm/s) were 28.1 ± 1.3, 8.6 ± 2.9, 20.3 ± 1.8, and 21.5 ± 1.6 for atorvastatin; 96.1 ± 7.1, 25.3 ± 3.5, 57.3 ± 9.8, and 48.2 ± 2.3 for fluvastatin; and 14.1 ± 1.9, 4.6 ± 1.7, 5.8 ± 0.7, and 6.6 ± 1.8 for rosuvastatin, respectively. Lovastatin and simvastatin showed no efflux in the vector control or knockdown cell monolayers in either lactone or acid forms. Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. On the other hand, neither the lactone nor the resulting acid of lovastatin and simvastatin was transported by P-gp, BCRP, or MRP2. The current study demonstrated that the transporter knockdown Caco-2 cells are useful tools for studying drug-transporter interactions and should help eliminate some of the ambiguity associated with the identification of drug-transporter interactions based on chemical inhibitors alone.
本研究的目的是确定负责酸性和内酯他汀类药物外排的外排转运体,方法是使用含有靶向人转运体的小发夹 RNA(shRNA)的慢病毒转导 Caco-2 细胞,敲低 P-糖蛋白(P-gp)、乳腺癌耐药蛋白(BCRP)或多药耐药相关蛋白 2(MRP2)的双向转运。用含有非靶向 shRNA 的慢病毒转导的细胞作为载体对照。阿托伐他汀、洛伐他汀和罗苏伐他汀显示出极低的顶端到基底(A 到 B)转运,使得 P(app,A-B) 值极不可靠,无法计算外排比。因此,使用 B 到 A 的通透性(P(app,B-A))值进行转运比较。按照载体对照、P-gp、BCRP 和 MRP2 敲低 Caco-2 细胞的顺序,阿托伐他汀的 P(app,B-A) 值(×10(-6),cm/s)分别为 28.1±1.3、8.6±2.9、20.3±1.8 和 21.5±1.6;氟伐他汀分别为 96.1±7.1、25.3±3.5、57.3±9.8 和 48.2±2.3;罗苏伐他汀分别为 14.1±1.9、4.6±1.7、5.8±0.7 和 6.6±1.8。洛伐他汀和辛伐他汀在载体对照或敲低细胞单层中均未以内酯或酸的形式表现出外排。结果表明,阿托伐他汀、氟伐他汀和罗苏伐他汀由 P-gp、BCRP 和 MRP2 转运。另一方面,洛伐他汀和辛伐他汀的内酯或酸均不由 P-gp、BCRP 或 MRP2 转运。本研究表明,转运体敲低 Caco-2 细胞是研究药物-转运体相互作用的有用工具,应有助于消除仅基于化学抑制剂鉴定药物-转运体相互作用所带来的一些模糊性。